



PTO Form 1449

Atty Docket No.	Application No.
112703-201	10/044,113
Applicant	<u> </u>
Ream et al	l .
Filing Date	Group:
January 9, 2002	Unknown

			U.S. PA	TENT DOCUMENTS			
Examiner's		Patent	Issue	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	Class	Code alara	Filing Date
Initials		Number	Date	Name	. Class	Subclass	If Appropriate
_\$H	<u>/</u>	1,298,670	04/01/1919	Cramer	+		
		1,629,461	05/17/1927	Berg et al.		<i></i>	
		2,892,753	06/30/1959	Schmidt et al.	+	1	NED
		2,990,328	06/27/1961	Lincoln	\	-CE	V
		3,011,949	12/05/1961	Bilotti	1 / 1	イレー	¥ 5005
		3,029,189	04/10/1962	Hardy, Jr. et al.	1	JAL "	2.000
		3,047,461	07/31/1962	Hardy, Jr. et al.	1	7	FR 180", CO.
		3,075,884	01/29/1963	Bilotti et al.		TEM CEN	100
		3,196,172	07/20/1965	Wright, Jr. et al.	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	19	LEK 1ECJ SOCO
		3,308,022	03/07/1967	Cummings et al.		\	
		3,498,964	03/03/1970	Hayashi		V	
		3,554,767	01/12/1971	aum		λ	
		3,590,057	06/29/1971	Suzuki et al.		Λ	
		3,845,217	10/29/1974	Ferno et al.			
		3,877,468	04/15/1975	Lichtneckert et al.			
		3,901,248	08/26/1975	Lichtneckert et al.			
		3,995,064	11/30/1976	Ehrgott et al.			
		4,154,814	05/15/1979	Hand et al.			
		4,238,475	12/09/1980	Witzel et al.			
		4,238,510	12/09/1980	Cherukuri et al.			
		4,283,408	08/11/1981	Hirata et al.			
		4,317,838	03/02/1982	Cherukuri et al.			
		4,374,858	2/22/1983	Glass et al.	1 1		
		4,378,374	3/29/1983	Reggio et al.			
		4,386,063	05/31/1983	Boden	+-1		
		4,400,372	08/23/1983	Muhler et al.			
		4,446,135	05/01/1984	Fountaine	11	<u> </u>	
		4,250,195	02/10/1981	Cherukuri et al.	+/		
	-	4,386,106	05/31/1983	Merrit et al.	+/		
	 	4,452,821	06/05/1984	Gergely	+/		
	 	4,459,311	07/10/1984	DeTora et al.		+	
	\bigvee	4,474,749	10/02/1984	Kruppa	1	 	
V (/	V	4,512,968	04/23/1985	Komiyama et al.	1	 	
SH	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	4,312,900	04/23/1903	ixonnyama et al.	 	<u> </u>	L



COPY OF PAPER ORIGINALLY FILE

District State Date Name Class Subclass Filing Date Name Name		13	-	<u> </u>	U.S. PAT	TENT DOCUMENTS			
4,533,556 08/06/1985 Piccolo et al.		iner's	24 TRADY	Patent					Filing Date
4,555,407 11/26/1985 Kramer et al. 4,563,345 01/07/1986 Arrick 4,639,368 01/27/1987 Niazi et al. 4,647,450 03/03/1987 Denick, Jr. et al. 4,711,774 12/08/1987 Denick, Jr. 4,711,774 12/08/1987 Denick, Jr. 4,711,774 12/08/1987 Denick, Jr. 4,737,366 04/12/1988 Gergely et al. 4,733,800 06/28/1988 Mozda 4,753,800 06/28/1988 Mozda 4,753,805 06/28/1988 Denick, Jr. et al. 4,753,805 06/28/1988 Denick, Jr. et al. 4,753,807 06/28/1988 Denick, Jr. et al. 4,753,809 07/05/1988 Denick, Jr. et al. 4,822,597 04/18/1989 Paust et al. 4,822,816 04/18/1989 Markham 4,828,820 05/09/1989 Glass et al. 4,832,934 05/23/1989 Fey 4,835,162 05/30/1989 Abood 4,849,227 07/18/1989 Cho 4,853,212 08/01/1989 Paust et al. 4,867,989 09/19/1989 Silva et al. 4,867,989 09/19/1989 Silva et al. 4,848,234 01/16/1990 Sharma et al. 4,908,211 03/13/1990 Paz 4,908,212 03/13/1990 Kwon et al. 4,908,212 03/13/1990 Kwon et al. 4,933,184 06/12/1990 Tsuk 4,933,184 06/12/1990 Tsuk 4,933,936 07/03/1990 Parmell 4,934,949 07/31/1990 Song et al. 4,968,716 11/06/1990 Markham 4,975,770 11/20/1990 Talapin et al. 4,975,770 12/04/1990 Kehoe 4,975,770 12/04/1990 Cherukuri et al.	Init	ials					Class	Subclass	If Appropriate
4,553,401 01/07/1986 Arrick 4,639,368 01/27/1987 Niazi et al. 4,647,450 03/03/1987 Peters et al. 4,711,774 12/08/1987 Denick, Jr. et al. 4,711,774 12/08/1987 Denick, Jr. et al. 4,713,360 04/12/1988 Gergely et al. 4,753,800 06/28/1988 Mozda 4,753,805 06/28/1988 Mozda 4,753,805 06/28/1988 Mozda 4,753,805 06/28/1988 Denick, Jr. et al. 4,753,805 06/28/1988 Denick, Jr. et al. 4,753,805 06/28/1989 Denick, Jr. et al. 4,822,597 04/18/1989 Denick, Jr. et al. 4,822,816 04/18/1989 Markham 4,822,816 04/18/1989 Faust et al. 4,823,820 05/09/1989 Glass et al. 4,833,162 05/30/1989 Fey 4,835,162 05/30/1989 Fey 4,835,162 05/30/1989 Fey 4,8467,989 09/19/1989 Silva et al. 4,884,227 07/18/1989 Cho 4,853,212 08/01/1989 Silva et al. 4,894,234 01/16/1990 Sharma et al. 4,908,211 03/13/1990 Paz 4,908,211 03/13/1990 Paz 4,908,211 03/13/1990 Sharma et al. 4,908,211 03/13/1990 Sharma et al. 4,908,3184 06/12/1990 Tsuk 4,933,184 06/12/1990 Tsuk 4,933,184 06/12/1990 Sharma et al. 4,94,94,949 07/31/1990 Sharma et al. 4,94,94,949 07/31/1990 Sharma et al. 4,963,369 10/16/1990 Sharma et al. 4,963,369 10/16/1990 Sharma et al. 4,963,369 10/16/1990 Sharma et al. 4,963,361 11/06/1990 Sharma et al. 4,963,369 10/16/1990 Sharma et al.	_\$	4	V				1		
4,753,805 06/28/1988 Cherukuri et al. 4,753,805 06/28/1988 Cherukuri et al. 4,758,424 07/19/1988 Denick, Jr. et al. 4,822,597 04/18/1989 Faust et al. 4,822,816 04/18/1989 Faust et al. 4,822,816 04/18/1989 Glass et al. 4,828,20 05/09/1989 Glass et al. 4,832,994 05/23/1989 Fey 4,835,162 05/30/1989 Abood 4,849,227 07/18/1989 Cho 4,867,989 09/19/1989 Silva et al. 4,867,989 09/19/1989 Silva et al. 4,882,152 11/21/1989 Yang et al. 4,894,234 01/16/1990 Sharma et al. 4,908,211 03/13/1990 Rwon et al. 4,929,474 05/29/1990 Yang 4,929,508 05/29/1990 Sharma et al. 4,933,184 06/12/1990 Tsuk 4,933,184 06/12/1990 Tsuk 4,935,242 06/19/1990 Sharma et al. 4,94,944,949 07/31/1990 Sharma et al. 4,968,511 11/06/1990 Song et al. 4,968,716 11/06/1990 Markham 4,971,787 11/20/1990 Cherukuri et al.							11		
4,753,805 06/28/1988 Cherukuri et al. 4,753,805 06/28/1988 Cherukuri et al. 4,758,424 07/19/1988 Denick, Jr. et al. 4,822,597 04/18/1989 Faust et al. 4,822,816 04/18/1989 Faust et al. 4,822,816 04/18/1989 Glass et al. 4,828,20 05/09/1989 Glass et al. 4,832,994 05/23/1989 Fey 4,835,162 05/30/1989 Abood 4,849,227 07/18/1989 Cho 4,867,989 09/19/1989 Silva et al. 4,867,989 09/19/1989 Silva et al. 4,882,152 11/21/1989 Yang et al. 4,894,234 01/16/1990 Sharma et al. 4,908,211 03/13/1990 Rwon et al. 4,929,474 05/29/1990 Yang 4,929,508 05/29/1990 Sharma et al. 4,933,184 06/12/1990 Tsuk 4,933,184 06/12/1990 Tsuk 4,935,242 06/19/1990 Sharma et al. 4,94,944,949 07/31/1990 Sharma et al. 4,968,511 11/06/1990 Song et al. 4,968,716 11/06/1990 Markham 4,971,787 11/20/1990 Cherukuri et al.				4,563,345					VED
4,753,805 06/28/1988 Cherukuri et al. 4,753,805 06/28/1988 Cherukuri et al. 4,758,424 07/19/1988 Denick, Jr. et al. 4,822,597 04/18/1989 Faust et al. 4,822,816 04/18/1989 Faust et al. 4,822,816 04/18/1989 Glass et al. 4,828,20 05/09/1989 Glass et al. 4,832,994 05/23/1989 Fey 4,835,162 05/30/1989 Abood 4,849,227 07/18/1989 Cho 4,867,989 09/19/1989 Silva et al. 4,867,989 09/19/1989 Silva et al. 4,882,152 11/21/1989 Yang et al. 4,894,234 01/16/1990 Sharma et al. 4,908,211 03/13/1990 Rwon et al. 4,929,474 05/29/1990 Yang 4,929,508 05/29/1990 Sharma et al. 4,933,184 06/12/1990 Tsuk 4,933,184 06/12/1990 Tsuk 4,935,242 06/19/1990 Sharma et al. 4,94,944,949 07/31/1990 Sharma et al. 4,968,511 11/06/1990 Song et al. 4,968,716 11/06/1990 Markham 4,971,787 11/20/1990 Cherukuri et al.		\		4,639,368	01/27/1987	Niazi et al.	[RECHI	VLD
4,753,805 06/28/1988 Cherukuri et al. 4,753,805 06/28/1988 Cherukuri et al. 4,758,424 07/19/1988 Denick, Jr. et al. 4,822,597 04/18/1989 Faust et al. 4,822,816 04/18/1989 Faust et al. 4,822,816 04/18/1989 Glass et al. 4,828,20 05/09/1989 Glass et al. 4,832,994 05/23/1989 Fey 4,835,162 05/30/1989 Abood 4,849,227 07/18/1989 Cho 4,867,989 09/19/1989 Silva et al. 4,867,989 09/19/1989 Silva et al. 4,882,152 11/21/1989 Yang et al. 4,894,234 01/16/1990 Sharma et al. 4,908,211 03/13/1990 Rwon et al. 4,929,474 05/29/1990 Yang 4,929,508 05/29/1990 Sharma et al. 4,933,184 06/12/1990 Tsuk 4,933,184 06/12/1990 Tsuk 4,935,242 06/19/1990 Sharma et al. 4,94,944,949 07/31/1990 Sharma et al. 4,968,511 11/06/1990 Song et al. 4,968,716 11/06/1990 Markham 4,971,787 11/20/1990 Cherukuri et al.				4,647,450	03/03/1987	Peters et al.	<u> </u>		v 3005
4,753,805 06/28/1988 Cherukuri et al. 4,753,805 06/28/1988 Cherukuri et al. 4,758,424 07/19/1988 Denick, Jr. et al. 4,822,597 04/18/1989 Faust et al. 4,822,816 04/18/1989 Faust et al. 4,822,816 04/18/1989 Glass et al. 4,828,20 05/09/1989 Glass et al. 4,832,994 05/23/1989 Fey 4,835,162 05/30/1989 Abood 4,849,227 07/18/1989 Cho 4,867,989 09/19/1989 Silva et al. 4,867,989 09/19/1989 Silva et al. 4,882,152 11/21/1989 Yang et al. 4,894,234 01/16/1990 Sharma et al. 4,908,211 03/13/1990 Rwon et al. 4,929,474 05/29/1990 Yang 4,929,508 05/29/1990 Sharma et al. 4,933,184 06/12/1990 Tsuk 4,933,184 06/12/1990 Tsuk 4,935,242 06/19/1990 Sharma et al. 4,94,944,949 07/31/1990 Sharma et al. 4,968,511 11/06/1990 Song et al. 4,968,716 11/06/1990 Markham 4,971,787 11/20/1990 Cherukuri et al.				4,711,774	12/08/1987	Denick, Jr. et al.		JUY	
4,753,805 06/28/1988 Cherukuri et al. 4,753,805 06/28/1988 Cherukuri et al. 4,758,424 07/19/1988 Denick, Jr. et al. 4,822,597 04/18/1989 Faust et al. 4,822,816 04/18/1989 Faust et al. 4,822,816 04/18/1989 Glass et al. 4,828,20 05/09/1989 Glass et al. 4,832,994 05/23/1989 Fey 4,835,162 05/30/1989 Abood 4,849,227 07/18/1989 Cho 4,867,989 09/19/1989 Silva et al. 4,867,989 09/19/1989 Silva et al. 4,882,152 11/21/1989 Yang et al. 4,894,234 01/16/1990 Sharma et al. 4,908,211 03/13/1990 Rwon et al. 4,929,474 05/29/1990 Yang 4,929,508 05/29/1990 Sharma et al. 4,933,184 06/12/1990 Tsuk 4,933,184 06/12/1990 Tsuk 4,935,242 06/19/1990 Sharma et al. 4,94,944,949 07/31/1990 Sharma et al. 4,968,511 11/06/1990 Song et al. 4,968,716 11/06/1990 Markham 4,971,787 11/20/1990 Cherukuri et al.				4,716,033	12/29/1987	Denick, Jr.			ER 1600 2900
4,753,805 06/28/1988 Cherukuri et al. 4,753,805 06/28/1988 Cherukuri et al. 4,758,424 07/19/1988 Denick, Jr. et al. 4,822,597 04/18/1989 Faust et al. 4,822,816 04/18/1989 Faust et al. 4,822,816 04/18/1989 Glass et al. 4,828,20 05/09/1989 Glass et al. 4,832,994 05/23/1989 Fey 4,835,162 05/30/1989 Abood 4,849,227 07/18/1989 Cho 4,867,989 09/19/1989 Silva et al. 4,867,989 09/19/1989 Silva et al. 4,882,152 11/21/1989 Yang et al. 4,894,234 01/16/1990 Sharma et al. 4,908,211 03/13/1990 Rwon et al. 4,929,474 05/29/1990 Yang 4,929,508 05/29/1990 Sharma et al. 4,933,184 06/12/1990 Tsuk 4,933,184 06/12/1990 Tsuk 4,935,242 06/19/1990 Sharma et al. 4,94,944,949 07/31/1990 Sharma et al. 4,968,511 11/06/1990 Song et al. 4,968,716 11/06/1990 Markham 4,971,787 11/20/1990 Cherukuri et al.				4,737,366	04/12/1988	Gergely et al.		ECH CENT	LI.
4,755,389 07/05/1988 Jones et al.				4,753,800	06/28/1988	Mozda			
4,758,424 07/19/1988 Denick, Jr. et al. 4,822,597 04/18/1989 Faust et al. 4,822,816 04/18/1989 Markham 4,828,820 05/09/1989 Glass et al. 4,832,994 05/23/1989 Fey 4,835,162 05/30/1989 Faust et al. 4,849,227 07/18/1989 Faust et al. 4,867,989 09/19/1989 Faust et al. 4,894,234 01/16/1990 Sharma et al. 4,908,211 03/13/1990 Paz 4,908,212 03/13/1990 Yang 4,929,508 05/29/1990 Sharma et al. 4,933,184 06/12/1990 Tsuk 4,933,242 06/19/1990 Sharma et al. 4,934,949 07/31/1990 Sharma et al. 4,944,949 07/31/1990 Sharma et al. 4,944,949 07/31/1990 Sharma et al. 4,944,949 07/31/1990 Sharma et al. 4,968,716 11/06/1990 D'Amelia et al. 4,971,787 11/20/1990 Cherukuri et al. 4,971,787 11/20/1990 Cherukuri et al.				4,753,805	06/28/1988	Cherukuri et al.			
4,822,597 04/18/1989 Faust et al. 4,822,816 04/18/1989 Markham 4,828,820 05/09/1989 Glass et al. 4,832,994 05/23/1989 Fey 4,835,162 05/30/1989 Abood 4,849,227 07/18/1989 Cho 4,867,989 09/19/1989 Silva et al. 4,882,152 11/21/1989 Yang et al. 4,894,234 01/16/1990 Sharma et al. 4,908,211 03/13/1990 Paz 4,908,212 03/13/1990 Won et al. 4,929,447 05/29/1990 Yang 4,929,508 05/29/1990 Sharma et al. 4,933,184 06/12/1990 Sharma et al. 4,935,242 06/19/1990 Sharma et al. 4,944,949 07/31/1990 Story et al. 4,968,511 11/06/1990 D'Amelia et al. 4,968,716 11/06/1990 Markham 4,971,787 11/20/1990 Cherukuri et al. 4,971,787 11/20/1990 Cherukuri et al. 4,978,537 12/18/1990 Song				4,755,389	07/05/1988	Jones et al.			
4,822,816 04/18/1989 Markham				4,758,424	07/19/1988	Denick, Jr. et al.			
4,828,820 05/09/1989 Glass et al.				4,822,597	04/18/1989	Faust et al.			
4,832,994 05/23/1989 Fey 4,835,162 05/30/1989 Abood 4,849,227 07/18/1989 Cho 4,853,212 08/01/1989 Faust et al. 4,867,989 09/19/1989 Silva et al. 4,882,152 11/21/1989 Yang et al. 4,894,234 01/16/1990 Sharma et al. 4,908,211 03/13/1990 Faz 4,908,212 03/13/1990 Kwon et al. 4,929,447 05/29/1990 Yang 4,929,508 05/29/1990 Sharma et al. 4,933,184 06/12/1990 Tsuk 4,935,242 06/19/1990 Sharma et al. 4,938,963 07/03/1990 Parnell 4,944,949 07/31/1990 Story et al. 4,968,511 11/06/1990 Song et al. 4,968,716 11/06/1990 Markham 4,971,787 11/20/1990 Cherukuri et al. 4,975,270 12/04/1990 Kehoe 4,978,537 12/18/1990 Song				4,822,816	04/18/1989	Markham			
4,835,162 05/30/1989 Abood 4,849,227 07/18/1989 Cho 4,853,212 08/01/1989 Faust et al. 4,867,989 09/19/1989 Silva et al. 4,882,152 11/21/1989 Yang et al. 4,894,234 01/16/1990 Sharma et al. 4,908,211 03/13/1990 Paz 4,908,212 03/13/1990 Kwon et al. 4,929,447 05/29/1990 Yang 4,929,508 05/29/1990 Sharma et al. 4,933,184 06/12/1990 Tsuk 4,935,242 06/19/1990 Sharma et al. 4,938,963 07/03/1990 Parnell 4,944,949 07/31/1990 Story et al. 4,963,369 10/16/1990 Song et al. 4,968,511 11/06/1990 Markham 4,971,079 11/20/1990 Cherukuri et al. 4,971,787 11/20/1990 Cherukuri et al. 4,975,270 12/04/1990 Kehoe				4,828,820	05/09/1989	Glass et al.			
4,849,227 07/18/1989 Cho				4,832,994	05/23/1989	Fey	-	1	
4,853,212 08/01/1989 Faust et al. 4,867,989 09/19/1989 Silva et al. 4,882,152 11/21/1989 Yang et al. 4,894,234 01/16/1990 Sharma et al. 4,908,211 03/13/1990 Paz 4,908,212 03/13/1990 Kwon et al. 4,929,447 05/29/1990 Yang 4,929,508 05/29/1990 Sharma et al. 4,933,184 06/12/1990 Tsuk 4,935,242 06/19/1990 Sharma et al. 4,938,963 07/03/1990 Parnell 4,944,949 07/31/1990 Story et al. 4,968,511 11/06/1990 D'Amelia et al. 4,968,716 11/06/1990 Markham 4,971,079 11/20/1990 Talapin et al. 4,971,787 11/20/1990 Kehoe 4,978,537 12/18/1990 Song				4,835,162	05/30/1989	Abood		V	
4,867,989 09/19/1989 Silva et al. 4,882,152 11/21/1989 Yang et al. 4,894,234 01/16/1990 Sharma et al. 4,908,211 03/13/1990 Paz 4,908,212 03/13/1990 Kwon et al. 4,929,447 05/29/1990 Yang 4,929,508 05/29/1990 Sharma et al. 4,933,184 06/12/1990 Tsuk 4,935,242 06/19/1990 Sharma et al. 4,938,963 07/03/1990 Parnell 4,944,949 07/31/1990 Story et al. 4,968,511 11/06/1990 Song et al. 4,968,716 11/06/1990 Markham 4,971,079 11/20/1990 Cherukuri et al. 4,971,787 11/20/1990 Cherukuri et al. 4,978,537 12/18/1990 Song		-		4,849,227	07/18/1989	Cho		Λ	
4,882,152 11/21/1989 Yang et al. 4,894,234 01/16/1990 Sharma et al. 4,908,211 03/13/1990 Paz 4,908,212 03/13/1990 Kwon et al. 4,929,447 05/29/1990 Yang 4,929,508 05/29/1990 Sharma et al. 4,933,184 06/12/1990 Tsuk 4,938,963 07/03/1990 Parnell 4,938,963 07/03/1990 Parnell 4,944,949 07/31/1990 Story et al. 4,968,511 11/06/1990 Song et al. 4,968,716 11/06/1990 Markham 4,971,787 11/20/1990 Cherukuri et al. 4,975,270 12/04/1990 Kehoe 4,978,537 12/18/1990 Song				4,853,212	08/01/1989	Faust et al.			
4,894,234 01/16/1990 Sharma et al. 4,908,211 03/13/1990 Paz 4,908,212 03/13/1990 Kwon et al. 4,929,447 05/29/1990 Yang 4,929,508 05/29/1990 Sharma et al. 4,933,184 06/12/1990 Tsuk 4,935,242 06/19/1990 Sharma et al. 4,938,963 07/03/1990 Parnell 4,944,949 07/31/1990 Story et al. 4,968,311 11/06/1990 Song et al. 4,968,716 11/06/1990 Markham 4,971,079 11/20/1990 Cherukuri et al. 4,971,787 11/20/1990 Cherukuri et al. 4,975,270 12/04/1990 Kehoe 4,978,537 12/18/1990 Song				4,867,989	09/19/1989	Silva et al.			
4,908,211 03/13/1990 Kwon et al. 4,908,212 03/13/1990 Kwon et al. 4,929,447 05/29/1990 Yang 4,929,508 05/29/1990 Sharma et al. 4,933,184 06/12/1990 Tsuk 4,935,242 06/19/1990 Sharma et al. 4,938,963 07/03/1990 Parnell 4,944,949 07/31/1990 Story et al. 4,968,511 11/06/1990 D'Amelia et al. 4,968,511 11/06/1990 Markham 4,971,079 11/20/1990 Talapin et al. 4,971,787 11/20/1990 Cherukuri et al. 4,975,270 12/04/1990 Kehoe 4,978,537 12/18/1990 Song				4,882,152	11/21/1989	Yang et al.		\	
4,908,212 03/13/1990 Kwon et al. 4,929,447 05/29/1990 Yang 4,929,508 05/29/1990 Sharma et al. 4,933,184 06/12/1990 Tsuk 4,935,242 06/19/1990 Sharma et al. 4,938,963 07/03/1990 Parnell 4,944,949 07/31/1990 Story et al. 4,963,369 10/16/1990 Song et al. 4,968,511 11/06/1990 D'Amelia et al. 4,968,716 11/06/1990 Markham 4,971,787 11/20/1990 Cherukuri et al. 4,975,270 12/04/1990 Kehoe 4,978,537 12/18/1990 Song				4,894,234	01/16/1990	Sharma et al.		\ \	
4,929,447 05/29/1990 Yang 4,929,508 05/29/1990 Sharma et al. 4,933,184 06/12/1990 Tsuk 4,935,242 06/19/1990 Sharma et al. 4,938,963 07/03/1990 Parnell 4,944,949 07/31/1990 Story et al. 4,963,369 10/16/1990 Song et al. 4,968,511 11/06/1990 D'Amelia et al. 4,968,716 11/06/1990 Markham 4,971,079 11/20/1990 Cherukuri et al. 4,971,787 11/20/1990 Kehoe 4,978,537 12/18/1990 Song				4,908,211	03/13/1990	Paz			
4,929,508 05/29/1990 Sharma et al. 4,933,184 06/12/1990 Tsuk 4,935,242 06/19/1990 Sharma et al. 4,938,963 07/03/1990 Parnell 4,944,949 07/31/1990 Story et al. 4,963,369 10/16/1990 Song et al. 4,968,511 11/06/1990 D'Amelia et al. 4,968,716 11/06/1990 Markham 4,971,079 11/20/1990 Talapin et al. 4,971,787 11/20/1990 Cherukuri et al. 4,975,270 12/04/1990 Kehoe 4,978,537 12/18/1990 Song				4,908,212	03/13/1990	Kwon et al.	1 1		
4,933,184 06/12/1990 Tsuk 4,935,242 06/19/1990 Sharma et al. 4,938,963 07/03/1990 Parnell 4,944,949 07/31/1990 Story et al. 4,963,369 10/16/1990 Song et al. 4,968,511 11/06/1990 D'Amelia et al. 4,968,716 11/06/1990 Markham 4,971,079 11/20/1990 Talapin et al. 4,971,787 11/20/1990 Cherukuri et al. 4,975,270 12/04/1990 Kehoe 4,978,537 12/18/1990 Song				4,929,447	05/29/1990	Yang			
4,935,242 06/19/1990 Sharma et al. 4,938,963 07/03/1990 Parnell 4,944,949 07/31/1990 Story et al. 4,963,369 10/16/1990 Song et al. 4,968,511 11/06/1990 D'Amelia et al. 4,968,716 11/06/1990 Markham 4,971,079 11/20/1990 Talapin et al. 4,971,787 11/20/1990 Cherukuri et al. 4,975,270 12/04/1990 Kehoe 4,978,537 12/18/1990 Song				4,929,508	05/29/1990	Sharma et al.			
4,938,963 07/03/1990 Parnell 4,944,949 07/31/1990 Story et al. 4,963,369 10/16/1990 Song et al. 4,968,511 11/06/1990 D'Amelia et al. 4,968,716 11/06/1990 Markham 4,971,079 11/20/1990 Talapin et al. 4,971,787 11/20/1990 Cherukuri et al. 4,975,270 12/04/1990 Kehoe 4,978,537 12/18/1990 Song				4,933,184	06/12/1990	Tsuk	1 1		
4,944,949 07/31/1990 Story et al. 4,963,369 10/16/1990 Song et al. 4,968,511 11/06/1990 D'Amelia et al. 4,968,716 11/06/1990 Markham 4,971,079 11/20/1990 Talapin et al. 4,971,787 11/20/1990 Cherukuri et al. 4,975,270 12/04/1990 Kehoe 4,978,537 12/18/1990 Song				4,935,242	06/19/1990	Sharma et al.			
4,963,369 10/16/1990 Song et al. 4,968,511 11/06/1990 D'Amelia et al. 4,968,716 11/06/1990 Markham 4,971,079 11/20/1990 Talapin et al. 4,971,787 11/20/1990 Cherukuri et al. 4,975,270 12/04/1990 Kehoe 4,978,537 12/18/1990 Song				4,938,963	07/03/1990	Parnell	1 1		
4,968,511 11/06/1990 D'Amelia et al. 4,968,716 11/06/1990 Markham 4,971,079 11/20/1990 Talapin et al. 4,971,787 11/20/1990 Cherukuri et al. 4,975,270 12/04/1990 Kehoe 4,978,537 12/18/1990 Song				4,944,949	07/31/1990	Story et al.			
4,968,716 11/06/1990 Markham 4,971,079 11/20/1990 Talapin et al. 4,971,787 11/20/1990 Cherukuri et al. 4,975,270 12/04/1990 Kehoe 4,978,537 12/18/1990 Song		·		4,963,369	10/16/1990	Song et al.	1 /		
4,971,079 11/20/1990 Talapin et al. 4,971,787 11/20/1990 Cherukuri et al. 4,975,270 12/04/1990 Kehoe 4,978,537 12/18/1990 Song				4,968,511	11/06/1990	D'Amelia et al.	17		-
4,971,787 11/20/1990 Cherukuri et al. 4,975,270 12/04/1990 Kehoe 4,978,537 12/18/1990 Song				4,968,716	11/06/1990	Markham	1		
4,975,270 12/04/1990 Kehoe 4,978,537 12/18/1990 Song				4,971,079	11/20/1990	Talapin et al.		1	
4,978,537 12/18/1990 Song				4,971,787	11/20/1990	Cherukuri et al.	11	1	
4,570,337				4,975,270	12/04/1990	Kehoe	11		
V 4,997,659 03/05/1991 Yatka et al.	V		₩	4,978,537	12/18/1990	Song	1		1
	57	7	V	4,997,659	03/05/1991	Yatka et al.			

JUL 1 9 2002 E

3		<u>*</u>	U.S. PAT	TENT DOCUMENTS			
Examiner's Initials	& TRADE	Patent	Issue				Filing Date
Initials		Number	Date	Name	Class	Subclass	If Appropriate
.5//	<u>'~</u>	5,013,716	05/07/1991	Cherukuri et al.	1		
		5,015,464	05/14/1991	Strobridge	1		
		5,045,325	9/3/1991	Lesko et al.			
		5,070,085	12/03/1991	Markham			EN/ED
		5,110,608	5/5/1992	Cherukuri et al.		HFV	EIVED 2 4 2002
		5,124,156	06/23/1992	Shibata et al.			2 4 2002
		5,126,151	06/30/1992	Bodor et al.		JUL	
		5,139,787	08/18/1992	Broderick et al.		TEAUCEN	VTER 1600:2000
		5,139,794	8/18/1992	Patel et al.		IFOLIOF	
		5,154,927	10/13/1992	Song et al.			
		5,156,842	10/20/1992	Mulligan			
		5,179,122	01/12/1993	Greene et al.			
		5,182,099	01/26/1993	Jonsson et al.	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \		
		5,229,137	07/20/1993	Wolfe			
		5,244,670	09/14/1993	Upson et al.		\	
		5,284,657	02/08/1994	Lu et al.			
		5,286,500	02/15/1994	Synosky et al.		\/	
		5,294,433	3/15/1994	Singer et al.		Y	
		5,294,449	03/15/1994	Greenberg		/	
		5,340,566	08/23/1994	Curtis et al.		$/ \setminus$	
		5,378,131	01/03/1995	Greenberg			
		5,380,530	01/10/1995	Hill			
		5,380,535	01/10/1995	Geyer et al.			
		5,397,580	03/14/1995	Song et al.			
		5,410,028	04/25/1995	Asami et al.			
		5,419,919	05/30/1995	Song et al.			
-		5,433,960	07/18/1995	Meyers			
		5,445,834	08/29/1995	Burger et al.			
		5,455,286	10/03/1995	Amidon et al.			
		5,456,677	10/10/1995	Spector			
		5,487,902	01.30 1996	Andersen et al.	1		
		5,488,962	02/06/1996	Perfetti			
		5,494,685	02/27/1996	Tyrpin et al.			
		5,496,541	03/05/1996	Cutler			
		5,512,306	04/30/1996	Carlsson et al.			
		5,523,097	06/04/1996	Song et al.			
		5,534,272	07/09/1996	Bernstein			
SH	V	5,536,511	7/16/1996	Yatka			



<u></u>	%	- <u>*</u>	U.S. PA	TENT DOCUMENTS			
Examiner's	A TRA	Patent	Issue				Filing Date
Initials	ļ l	Number	Date	Name	Class	Subclass	If Appropriate
SH	<u></u>	5,543,160	08/06/1996	Song et al.	A		
		5,554,380	09/10/1996	Cuca et al.	1		
		5,569,477	10/29/1996	Nesbitt	1		1ED
		5,571,528	11/05/1996	Lee et al.	1	-CEI	7 -
		5,571,543	11/05/1996	Song et al.	1 5	SEOP.	2005
		5,576,344	11/19/1996	Sandler et al.	1,	11/2	10000
		5,580,590	12/03/1996	Hartman		39	ED 16001150
		5,582,855	12/10/1996	Cherukuri et al.		CEN	Ici,
		5,585,110	12/17/1996	Kalili et al.		TEUX	1EB 1800155900 1EB 1800155900
		5,593,685	01/14/1997	Bye et al.			
		5,601,858	2/11/1997	Mansukhani et al.			
		5,605,698	2/25/1997	Ueno			
		5,607,697	03/04/1997	Alkire et al.			
		5,618,517	04/08/1997	Miskewitz		\	
		5,628,986	05/13/1997	Sanker et al.			
		5,629,013	05/13/1997	Davis		\bigvee	
		5,629,026	05/13/1997	Davis		Y	
		5,629,035	05/13/1997	Miskewitz		/	
		5,645,853	07/08/1997	Winston et al.	•	Λ	
		5,651,987	7/29/1997	Fuisz			
		5,656,652	08/12/1997	Davis			
		5,665,386	09/09/1997	Benet et al.			
		5,665,406	9/9/1997	Reed et al.	1		
		5,667,802	12/16/1997	Grimberg			
		5,693,334	12/02/1997	Miskewitz			
		5,698,215	12/16/1997	Kalili et al.			
		5,702,687	12/30/1997	Miskewitz			
		5,711,961	01/27/1998	Reiner et al.		1	
		5,716,928	02/10/1998	Benet et al.			
		5,736,175	04/07/1998	Cea et al.			
		5,744,164	04/28/1998	Chauffard et al.	<u> </u>		
		5,753,255	05/19/1998	Chavkin et al.			
		5.756,074	05/26/1998	Ascione et al.			
		5,800,847	09/01/1998	Song et al.	1/		
		5,824,291	10/20/1998	Howard			
		5,834,002	11/10/1998	Athanikar	11	1	
		5,846,557	12/08/1998	Eisenstadt et al.	<u> </u>		\
54	V	5,854,267	12/29/1998	Berlin et al.			
	<u> </u>		L			·	

JUL 1 9 2002 🐇

U.S. PATENT DOCUMENTS Filing Date Examine Patent Issue Subclass Number Date Name Class If Appropriate Initials 5,858,383 01/12/1999 Precopio SH RECEVIEN EN CONTERNO 5,858,412 01/12/1990 Staniforth et al. 5,858,413 01/12/1999 Jettka et al. Yajima et al. 5,858,423 01/12/1999 5,866,179 02/02/1999 Testa 5,877,173 03/02/1999 Olney et al. 5,882,702 03/16/1999 Abdel-Malik et al. 03/30/1999 Sandborn et al. 5,889,028 03/30/1999 5,889,029 Rolf 5,897,891 04/27/1999 Godfrey 05/04/1999 Cutler 5,900,230 06/15/1999 Pan et al. 5,912,007 06/15/1999 Huziinec et al. 5,912,030 06/29/1999 Record et al. 5,916,606 5,922,346 07/13/1999 Hersh 5,922,347 7/13/1999 Hausler et al. 07/27/1999 Yang et al. 5,928,664 Winston et al. 5,958,380 09/28/1999 Robinson et al. 5,958,472 09/28/1999 5,980,955 11/09/1999 Grennberg et al. 5,989,588 11/23/1999 Korn et al. 02/15/2000 Ream et al. 6,024,988 Gurol et al. 6,066,342 05/23/2000 6,077,524 6/20/2000 Bolder et al. 6,090,412 07/18/2000 Hashimoto et al. 6,165,516 12/26/2000 Gudas et al. 6,200,604 03/13/2001 Pather et al. Itoh et al. 2/24/2001 6,221,402 07/10/2001 Athanikar 6,258,376 Ream et al. 6,290,985 9/18/2001 6.303.159 10.16.2001 Barkalow et al. 11/1/2001 Anthanikar 2001/0036445 11/27/2001 Ream et al. 6,322,806 2002/0012633 1/31/2002 Gmunder et al. 2002/0022057 2/21/2002 Battery et al. Urnezis et al. 6,350,480 2/26/2002 6,355,265 3/12/2002 Ream et al. 2002/0039560 4/4/2002 Ream et al.



TEM &	IB VO.		U.S. PA	TENT APPLICATIONS			
Examiner's		Application	Filing				Filing Date
Initials		Number	Date	Name	Class	Subclass	If Appropriate
SH		09/286,818	4/6/1999	Ream, et al.	1	/	
		09/421,905	10/20/1999	Ream, et al.	<u> </u>		
		09/510,878	2/23/2000	Ream, et al.			
		09/535,458	3/24/2000	Ream, et al.	<u> </u>		
		09/552,290	4/19/2000	Song, et al.		/,<	\mathcal{O}
		09/591,256	6/9/2000	Zyck, et al.			
		09/592,400	6/13/2000	Ream et al.		CX	<i>~</i>
		09/618,808	7/18/2000	Ream, et al.	de		Sagar
		09/621,643	7/21/2000	Johnson, et al.	11	11/2	colisso
		09/621,780	7/21/2000	McGrew, et al.		7 <	8,100
		09/631,326	8/3/2000	Ream, et al.		CEMI	1002 1002
		09/651,514	8/30/2000	Tyrpin, et al.		KROKO	
		09/653,669	9/1/2000	Zyck, et al.		1)	
		09/654,464	9/1/2000	Zyck, et al.		X	
		09/671,552	9/27/2000	Ream, et al.		Λ	
		09/681,935	6/28/2001	Seielstad, et al.			
		09/714,571	11/16/2000	Gmunder et al.			
		09/747,300	12/22/2000	Zyck, et al.			
		09/747,323	12/22/2000	Zyck, et al.			
		09/748,699	12/22/2000	Zyck, et al.			
		09/759,561	1/11/2001	Ream, et al.		\	
		09/759,838	1/11/2001	Ream, et al.			
		09/924,914	8/8/2001	Ream et al.			
		09/955,870	9/19/01	Ream et al.			
		09/956,445	9/19/01	Gmunder et al.		1	
		09/990,628	11/13/01	Ream et al.			
1,1/	1,	09/992,122	11/13/01	Ream et al.		1	
V	V	10/024,631	12/17/01	Johnson et al.			
54	/	10/044,113	1/9/2002	Ream et al.			

	FOREIGN PATENT DOCUMENTS										
								Trans	slation		
			Document Number	Date	Country	Class	Subclass	Yes	No		
SH	/	レ	0 934 596	8/21/1963	United Kingdom	_					
		1	0 963 518	07/08/1964	United Kingdom						
			2,345,938	03/29/1976	France	J					
			1 489 832	10/26/1977	United Kingdom						
			43 42 568	06/01/1984	Germany						
Ι.		,	84/02271	06/21/1984	WIPO						
V		$\sqrt{}$	0,202,819	11/26/1986	Europe						
SH		V	0,217,109	04/08/1987	Europe						

2007 2			TOREIGN	PATENT DOCUME	in 13		Trans	slation
2002 E		Document Number	Date	Country	Class	Subclass	Yes	No
SH	<i>'</i>	2,181,646	04/29/1987	United Kingdom	1	/		
	1	0 221 850	05/13/1987	Europe				
		0,239,541	09/30/1987	Europe	1		Os.	
		91-112450	09/24/1989	Japan		LN	10	
		2 635 441	02/23/1990	France		100	5005	an.
		0,371,584	06/06/1990	Europe	\ <	XVI.	J. Dr.	0/52
		90/12511	11/01/1990	WIPO		100	CRIV	9-
		90/12583	11/01/1990	WIPO			ENIA	
		91-251533	11/11/1991	Japan		1,500		
ľ		92/06680	04/30/1992	WIPO		ECT OF		
		2,706,771	06/21/1993	France			_	
		94-2868	04/05/1994	South Korea				-
		94-303911	11/01/1994	Japan		1		
		95/00038	01/05/1995	WIPO				
		95/00039	01/05/1995	WIPO		V		
		95/10290	04/30/1995	WIPO		1		
		96/00070	01/04/1996	WIPO		Λ		
_		96-19370	01/23/1996	Japan				
-		96/03975	02/15/1996	WIPO				11.10
		86/242561	10/28/1996	Japan				
		97/21424	06/19/1997	WIPO	1			
		01273487	07/08/1997	Italy				
		01293655	7/29/1997	Italy				
		97/24036	7/10/1997	WIPO		1	-	
		98/23165	06/04/1998	WIPO				
		98/23166	06/04/1998	WIPO				
		98/23167	06/04/1998	WIPO				
		0 273 809	07/06/1998	Europe				
		99/33352	07/08/1999	WIPO				
		99/44436	09/10/1999	WIPO	' 	1		
		00/13523	03/16/2000	WIPO		1		
		00/35296	06/22/2000	WIPO				
		00/35298	06/22/2000	WIPO			_	
		00/38532	07/06/2000	WIPO				
	1/	99/27798	06/10/1999	WIPO		1		
SH		02/13781	02/21/2002	WIPO	 			



/o`		c.	
nn	19	2002	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
1,5	H	DOME!	Akitoshi et al., Abstract "Acceleration of Transdermal Absorption of Pharmaceuticals by Essential Oils and Organic Solvents," Chem. Abst., 112:125228t, 1990.
	& TR	Mr.	Adams, M.W., d-Alpha Tocopheryl Polyethylene glycol 1000 Succinate (Eastman vitamin E TPGS) as an Emulsifier and Bioenhancer for Drugs and Lipophilic Compounds, 6th International Conference on Pharmaceutical Technology, Paris, 2-4 June, 1992.
			Allen, et al., "Exclusive Guide to Wellness Foods and Nutraceuticals", Food Processing (Special Supplement), (March, 1999)
			Beckett, A.H., et al.; "Buccal absorption of basic drugs and its application as an in vivo model of passive drug transfer through lipid membranes" (1967) J. Pharm. Pharmac., 19 Suppl. 31S-41S.
			Bradford, A Rapid and Sensitive Method for the Quantification of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding, Analytical Biochemistry, 72:248-254 (1976). Broihier, Kitty R.D., 'Foods of Tomorrow, Milking The Nutrition Market', Food Processing, (March,
			1999), pp. 41, 42 and 44 Broihier, Kitty R.D., "Tea Time For Nutraceuticals, New Black, Green Tea Products Brew Up a Bevy Of Health Benefits", Food Processing; (March, 1999), pp. 59, 61 and 63
			Calanchi et al., "Taste-masking of oral formulations", Eurand International SpA, Pharmaceutical Manufacturing International, 1996 (5 pages).
			Chang et al., "The Effect of Water-Soluble Vitamin E on Cyclosporine Pharmacokinetics in Healthy Volunteers," Abstract in American Society to Clinical Pharmacology and Therapeutics, 57(2):163, Feb. 1995.
			Elliott, James G., "Application of Antioxidant Vitamins in Foods and Beverages" Food Technology, (February, 1999), pp. 46-48
			The Eurand Group, Brochure (undated) (published at least before November 27, 1996), (16 pages).
			"Flavor Encapsulation Technologies, Flavor Unit Sweet, Product Management", H&R (undated) (published at least before November 27, 1996), 25 pages.
			Gumtech article from the Internet "Customized Solutions For Customer Brands", printed 10/18/2000, http://www.gum-tech.com/cus-brands.html , 3 pages
			Hebert, Mary F. et al.; "Bioavailability of Cyclosporine with Concomitant Rifampin Administration is Markedly Less Than Predicted by Hepatic Enzyme Induction" (1992) Clin. Pharmacol. Ther. 52:453-457.
			Hertiage Consumer Products Co. article from the Internet "Cosmetics and Toiletries, The Heritage Story", printed 07/20/2000, http://www.cnewsusa.com/Connecticut/14997.html>, 1 page
			Kronbach, Thomas et al.; "Oxidation of Midazolam and Triazolam by Human Liver Cytochrome P450IIIA4" (1989) <i>Molec. Pharm.</i> 36:89-96.
			Lalka et al.; "The Hepatic First-Pass Metabolism of Problematic Drugs" (1993) J. Clin. Pharmacol. 33:657-669.
			Lum et al.; "Clinical Trials of Modulation of Multidrug Resistance. Pharmacokinetic and Pharmacodynamic Considerations" (1993) Cancer 72:3502-3514.
			Merck Index, 11 th Ed., #1635 "Caffeine" (1989), p. 248.
			Merck Index, 12 th Ed., #2337 "Cimetidine" (1996), p. 383.
			Merck Index, 12 th Ed., #3264 "Dimethicone" (1996), p. 544. Merck Index, 12 th Ed., #3972 "Famotidine" (1996), p. 667.
			Merck Index, 12 th Ed., #2337 "Cimetidine" (1996), p. 383. Merck Index, 12 th Ed., #3264 "Dimethicone" (1996), p. 544. Merck Index, 12 th Ed., #3972 "Famotidine" (1996), p. 667. Merck Index, 12 th Ed., #6758 "Nizatidine" (1996), p. 1143. Merck Index, 12 th Ed., #6977 "Omeprazole" (1996), p. 1174. Merck Index, 12 th Ed., #8272 "Rabeprazole" (1996), p. 1392. Merck Index, 12 th Ed., #8286 "Ranitidine" (1996), p. 1395.
	<u> </u>		Merck Index, 12 Ed., #0/38 :Nizatidine (1990), p. 1143.
	 ,_		Merck Index, 12th Ed., #6977 "Omeprazole" (1996), p. 1174.
\\	<u>V</u> _	V	Merck Index, 12 th Ed., #8272 "Rabeprazole" (1996), p. 1392.
S	4	V	Merck Index, 12 th Ed., #8286 "Ranitidine" (1996), p. 1395.

COPY OF PAPERS ORIGINALLY FILED



JUL 1	9 2	XX	
		- 7	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
3/2	3 HA	SENT P	"In the Thompsers" (1990) Crit. Rev. Ther. Drug Carrier Sys., 7.1 33.
O T	3 140		Muranishi, Shozo; "Absorption Elinancets" (1996) Nielsen et al., P-Glycoprotein as Multidrug Transporter: A Critical Review of Current Multidrug Nielsen et al., P-Glycoprotein as Multidrug Transporter: A Critical Review of Current Multidrug Nielsen et al., P-Glycoprotein as Multidrug Transporter: A Critical Review of Current Multidrug
- []		7	Nielsen et al., P-Glycoprotein as Multidrug Transporter. A Critical Victoria, 1130-169-183 (1992).
1	1		Nielsen et al., P-Glycoprotein as Muttiding Haisporter. Resistant Cell Lines, Chimica et Biophysica Acta., 1139:169-183 (1992). Resistant Cell Lines, Chimica et Biophysica Acta., 1139:169-183 (1992).
╌		+-	Product package "Aspergum" distributed by Heritage Consumer
- 1	į		November 27, 1995)
+-	-	+	de de la cura Dental Gum" distributed by Dieatti Asare, mei (1997)
		1_	Product package "BreathAstite Dental Gum" by Gumtech International, Inc. Product package "Chew & Sooth Zinc Dietary Supplement Gum" by Gumtech International, Inc.
	Ì	1	Product package Chew & South East Vision by
		1	(undated) Product package "CHOOZ Antacid/Calcium Supplement with Calcium Carbonate" distributed by
			Heritage Consumer Products Co. Heritage Consumer Products Co. Heritage Consumer Products Co.
1_			Heritage Consumer Products Co. Product package "Dental Care the Baking Soda Gum" distributed by Church & Dwight Co., Inc. (1998)
		1	Product package "Dental Care the Baking South
-+		╁╴	Product package "Trident Advantage with Baking Soda" distributed by Warner-Lambert Co. (1998) Product package "Trident Advantage with Baking Soda" distributed by Warner-Lambert Co. (1998)
- 1			Product package for Stay Alert Caffeine Supplement Gum, distributed by Amurol Confections
			Product package for Stay Alert Carterine Supply
- 1		1_	Company (first quarter 1998) Rabeprazole article from the Internet "Rabeprazole: Pharmacokinetics and Safety in the Elderly" Rabeprazole article from the Internet "Rabeprazole: Pharmacokinetics and Safety in the Elderly" Rabeprazole article from the Internet "Rabeprazole: Pharmacokinetics and Safety in the Elderly"
			Rabeprazole article from the Internet "Rabeprazole: Pharmacokhietics and Gardy Rabeprazole article from the Internet "Rabeprazole: Pharmacokhietics and Gardy Rabeprazole articles are art
İ			printed 09/22/2000, http://www.mmhc.com/cg.articles.cog/90/7talin-pinted-mm- , I Somberg et al.; "The Clinical Implications of First-Pass Metabolism: Treatment Strategies for the Somberg et al.; "The Clinical Implications of First-Pass Metabolism: Treatment Strategies for the Somberg et al.; "The Clinical Implications of First-Pass Metabolism: Treatment Strategies for the Somberg et al.; "The Clinical Implications of First-Pass Metabolism: Treatment Strategies for the Somberg et al.; "The Clinical Implications of First-Pass Metabolism: Treatment Strategies for the Somberg et al.; "The Clinical Implications of First-Pass Metabolism: Treatment Strategies for the Somberg et al.; "The Clinical Implications of First-Pass Metabolism: Treatment Strategies for the Somberg et al.; "The Clinical Implications of First-Pass Metabolism: Treatment Strategies for the Somberg et al.; "The Clinical Implications of First-Pass Metabolism: Treatment Strategies for the Somberg et al.; "The Clinical Implications of First-Pass Metabolism: Treatment Strategies for the Somberg et al.; "The Clinical Implications of First-Pass Metabolism: Treatment Strategies for the Somberg et al.; "The Clinical Implications of First-Pass Metabolism: The Somberg et al.; "The Clinical Implications of First-Pass Metabolism: The Somberg et al.; "The Clinical Implications of First-Pass Metabolism: The Somberg et al.; "The Somberg et
		$\neg \Gamma$	Somberg et al.; "The Clinical Implications of the Clinical Implications of
1			Specialty Minerals Inc. Brochure, April 1998, 19 pages.
			Specialty Minerals Inc. Brochule, April 1996, 1993 Tam, Yun K.; "Individual Variation in First-Pass Metabolism" (1993) Clin. Pharmacokinet. 25:300
	\vdash	-	Tam Yun K.: "Individual Variation in First-Pass Metabolism" (1993) Citi. I narmassum
[- 1	328. The United States Pharmacopeia The National Formulary - "General Information", dated January 1 The United States Pharmacopeia The National Formulary - "General Information", dated January 1 The United States Pharmacopeia The National Formulary - "General Information", dated January 1
	┞╼═┤	+	The United States Pharmacopeia The National Formulary - General Information, and
		-	1990 pp 1624-1625 and pp 1696-1697 1990 pp 1624-1625 and pp 1696-1697 The beneament: An Overview" (1989) Pharmaco
		-+-	1990 pp 1624-1625 and pp 1696-1697 Van Hoogdalem et al.; "Intestinal Drug Absorption Enhancement: An Overview" (1989) Pharmaco
			Ther. 44:407-443.
	├ ─		Ther. 44:407-443. Vreeland, C. Curtis, "Nutraceuticals Fuel Confectionery Growth" Candy R&D, (March, 1999), pp. 29
	1		31-32, 34-35.
	├—	┼╂┈	31-32, 34-35. Warren et al.; "Increased Accumulation of Drugs in Multidrug-Resistant Cell Induced by Liposome." 152-3241, 3245
	l]]	Waltern (1992) Cancer Research 52:3241-3245. Watkins, Paul B.; "The Role of Cytochromes P-450 in Cyclosporine Metabolism" (1990) J. Am. Aca
		├-	Warkins Paul B.: "The Role of Cytochromes P-430 in Cyclospornic Metabothers
	1	11	Dermacol. 23:1301-1309.
	╀	┼╂╌	Weinberg, David. S., et al.; "Sublingal absorption of selected opioid analysis (1997)
	1		Ther., 44: 335-342.
	╂	┼╂╌	Wrighton et al.; "In Vitro Methods for Assessing Human Hepatic Biog Methods
	1	11	Development" (1993) 25:453-484.
	+-	++	Wu et al.: "Use of IV and Oral Drug Levels from Cyclospotent (CSA) Physical Dispersect ppdm8185.
1	Ψ	+1	Wu et al.; "Use of IV and Oral Drug Levels from Cyclosporetic (csar) Manual Wu et al.; "Use of IV and Oral Drug Levels from Cyclosporetic (csar) Manual Res. 10:abstract ppdm8185. Differentiate Gut Absorption and Metabolism" (1993) Pharm. Res. 10:abstract ppdm8185.
	4	+*	
	CL	4	Resistance in Human Loukeline Cens (1969)
	<u> </u>	_L'V	Date Considered: 9/1/03
Exa	min	er:	Initial if citation considered, whether or not citation is in conformance with PEP Section 609; Draw li
*10.	ir		Initial if citation considered, whether or not citation is in comordinated with next communication

*Examiner: Initial if citation considered, whether or not citation is in conformance with PEP Section 609; Draw line *Examiner: Initial if citation considered, whether or not citation is in conformance/with PEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Examiner: Initial if citation considered, whether or not citation is in conformance/with PEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Examiner: Initial if citation considered, whether or not citation is in conformance/with PEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.